tiprankstipranks
Advertisement
Advertisement

SABS Stock Latest News

SAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target
RatingsSAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target
1d ago
SABS
SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained
PremiumRatings
SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained
2d ago
SABS
SAB Biotherapeutics initiated with a Buy at Citi
PremiumThe Fly
SAB Biotherapeutics initiated with a Buy at Citi
26d ago
SABS
SAB Biotherapeutics initiated with a Buy at Jefferies
PremiumThe Fly
SAB Biotherapeutics initiated with a Buy at Jefferies
28d ago
SABS
SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright
PremiumThe Fly
SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright
1M ago
SABS
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142
PremiumCompany AnnouncementsSAB Biotherapeutics Signs Manufacturing Pact for SAB-142
1M ago
8K
SABS
Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics
Premium
The Fly
Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics
2M ago
EBS
SABS
Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst
Premium
Ratings
Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst
2M ago
SABS
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
PremiumCompany Announcements
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
2M ago
8K
SABS
SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw
3M ago
SABS
SABS Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SABS Upcoming Earnings Report: What to Expect?
3M ago
SABS
SAB Biotherapeutics Launches Major Equity Financing Offering
PremiumCompany Announcements
SAB Biotherapeutics Launches Major Equity Financing Offering
3M ago
8K
SABS
SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85
PremiumThe FlySAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85
3M ago
SABS
SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07
Premium
The Fly
SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07
3M ago
SABS
SAB Biotherapeutics announces common stock offering, no amount given
Premium
The Fly
SAB Biotherapeutics announces common stock offering, no amount given
3M ago
SABS
SAB Biotherapeutics price target raised to $14 from $12 at Chardan
PremiumThe Fly
SAB Biotherapeutics price target raised to $14 from $12 at Chardan
3M ago
SABS
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
PremiumCompany Announcements
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
3M ago
8K
SABS
SAB Biotherapeutics announces additional Phase 1 data for SAB-142
PremiumThe Fly
SAB Biotherapeutics announces additional Phase 1 data for SAB-142
3M ago
SABS
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
PremiumStock Analysis & Ideas
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
5M ago
ABOS
SABS
SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook
PremiumCompany AnnouncementsSAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook
5M ago
8K
SABS
SAB Biotherapeutics Appoints New Independent Board Chair, Directors
Premium
Company Announcements
SAB Biotherapeutics Appoints New Independent Board Chair, Directors
5M ago
8K
SABS
SAB Biotherapeutics initiated with a Buy at UBS
Premium
The Fly
SAB Biotherapeutics initiated with a Buy at UBS
5M ago
SABS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >